跳至主要内容
临床试验/NL-OMON46703
NL-OMON46703已完成不适用

A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954)in Healthy Male Subjects - Microtracer TAK-954 Healthy Adult Male Subjects

Millennium Pharmaceuticals Inc0 个研究点目标入组 6 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • -healthy male subjects
  • -18-55 yrs, inclusive
  • -BMI: >=18 and <=30 kg/m2 and a body weight >50 kg at the screening visit.
  • -non-smoking

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

研究者

相似试验

已完成
不适用
A Phase 1, Single-Center, Open-label, Infusion Dose Optimization Study of ABP-700 in Healthy, Adult Subjectsanesthesia
NL-OMON42498Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company)80
尚未招募
1 期
Mesenchymal Stem Cell Therapy For Covid 19
CTRI/2020/08/027043eurogen Brain and Spine Institute
已完成
不适用
Phase1 clinical study of a single intravenous dose of TRM-1106 in healthy Japanese adult me
JPRN-UMIN000005914Terumo Corporation30
进行中(未招募)
1 期
An early stage study looking at how much betrixaban gets into the blood of young people after they take a single capsule, and to see if it is safe to do so.Pediatric patients who are assessed to be at risk for Venous thromboembolism (VTE) but does not require immediate anticoagulant therapy, for example:a. Has previous thrombosis and completed a course of anti-coagulant therapy, and is considered to have a risk for recurrence of VTE, orb. Has any stable disease with a risk for arterial or venous thrombotic disorder, orc. Has any functional CVAD (Central Venous Access Device) in the upper or lower venous system.MedDRA version: 20.0Level: PTClassification code 10053468Term: Anticoagulant therapySystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2018-002562-40-GBPortola Pharma UK Ltd33
尚未招募
1 期
A Study of the Pharmacokinetics and Safety of a Single Dose of Lenabasum in Subjects with Hepatic Impairment Compared with Matched Healthy Controls
ACTRN12620000712909Corbus Pharmaceuticals Inc32
A Phase 1, Open-label, Single Intravenous Infusion... | 临床试验